Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Study Information
Alliance Study ID: NCCTG-N0871
NCT Study ID (ClinicalTrials.gov): NCT00936702
Alliance Committee: Experimental Therapeutics
Disease or Cancer Type: Other Cancer
Alliance Study Chair: Matthew P. Goetz, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated cancer of unknown primary.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information